Cynosure Management, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Cynosure Management, LLC
- $648 Million
- Q4 2024
A detailed history of Cynosure Management, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Cynosure Management, LLC holds 14,048 shares of CPRX stock, worth $295,288. This represents 0.05% of its overall portfolio holdings.
Number of Shares
14,048
Previous 17,736
20.79%
Holding current value
$295,288
Previous $352,000
16.76%
% of portfolio
0.05%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding CPRX
# of Institutions
348Shares Held
98.5MCall Options Held
13.4KPut Options Held
11.7K-
Black Rock Inc. New York, NY18.7MShares$393 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$177 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$122 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.13MShares$65.9 Million1.62% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$63.3 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.16B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...